Developer docs
API playgroundTry for free, no card

Search company profiles

Anupam Rasayan

Full company profile

uuid0002gr3

Namestring
Anupam Rasayan
Legal namestring
Anupam Rasayan India Limited
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Anupam Rasayan India Limited is a publicly listed (NSE: ANURAS) custom manufacturer of specialty chemicals headquartered in Surat, Gujarat, India, with 1,700+ employees including 90+ scientists and 40+ years of industry experience. The company operates eight manufacturing facilities — six in India and two in the United States (acquired via Jayhawk Fine Chemicals in February 2026) — with a combined installed capacity of approximately 30,000+ MPTA, producing 60+ complex molecules across 30+ commercial chemistries for 80+ global customers in agrochemicals (51% of pre-acquisition revenue), pharmaceuticals, and performance materials/electronics.

The company's core technology is a proprietary continuous flow chemistry platform, which in June 2026 enabled it to become the world's first commercial producer of Ethyl trifluoroacetate (ETFA) — a fluorinated building block serving pharma, life sciences, and performance materials end-markets with a $500-600 million global addressable market. Its products include custom-synthesized agrochemical intermediates and active ingredients, pharmaceutical intermediates and (via Bliss GVS Pharma, announced May 2026) finished dosage formulations including suppositories, injectables, and tablets manufactured at US FDA, WHO-GMP, and EU-GMP approved facilities, and advanced custom synthesis for electronics, aerospace, energy, and polymers via the Jayhawk acquisition.

Anupam Rasayan generates revenue through a B2B custom synthesis and contract development/manufacturing (CDMO) model with quote-based pricing under long-term contracts. FY26 revenue reached Rs 23,836 million (approximately $285M USD), up 65% YoY, with FY26 net profit of Rs 170.12 crore (+82.24% YoY). The company sells directly to enterprise customers in regulated markets via wholly-owned subsidiaries in the US (Delaware, Kansas), Europe (Basel), Japan (Tokyo), and the UAE (Dubai). Recent strategic positioning includes an EcoVadis Silver Medal (Top 15% globally, score 77), UN Global Compact signatory status, and a 2027 net-zero energy target with 39.5% renewable energy share already achieved.

Short descriptiontext

Anupam Rasayan is a publicly listed Indian custom manufacturer of specialty chemicals, producing complex molecules via proprietary continuous flow chemistry for 80+ global pharma, agrochemical, and performance-materials customers across eight manufacturing facilities in India and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSachin, India
HQ citystring
Sachin
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty chemicals manufacturing, custom chemical synthesis, pharmaceutical intermediates, agrochemical intermediates, continuous flow chemistry
Industry3 codes
PRIMARYAFABAIAI
Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Agrochemical Formulation & Toll Manufacturing
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Industrial Organic Chemicals2860
  • Chemicals & Allied Products2800
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Chemicals Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Specialty Chemicals Manufacturing
TypeOne Time License
Description

Custom manufacturing of specialty chemicals for agrochemicals (51% of revenue pre-acquisition), pharmaceuticals, and performance materials segments. Revenue generated through long-term contracts and custom synthesis projects with 80+ global customers.

manufacturingtodayindia.com
2Custom Synthesis Services
TypeProfessional Services
Description

Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications. Contributed to significant revenue growth with 65% YoY increase in FY26.

manufacturingtodayindia.com
3Pharmaceutical Formulations
TypeOne Time License
Description

Entry into finished dosage formulations through acquisition of Bliss GVS Pharma, expanding from key starting materials into finished dosage formulations with access to US FDA, WHO-GMP, and EU-GMP approved facilities.

cnbctv18.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom manufacturing services with quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

B2B pricing model - no public pricing available; services quoted based on specific customer requirements, volume, and complexity of molecules

anupamrasayan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anupam Rasayan is a custom manufacturer of specialty chemicals operating 8 manufacturing facilities across India and the United States with combined capacity of about 66,000 metric tonnes. The company produces 60+ complex molecules across 30+ commercial chemistries, serving agrochemicals, pharmaceuticals, performance materials, and life sciences sectors. It also operates a CDMO business for custom synthesis of complex molecules and has expanded into finished dosage pharmaceutical formulations through the Bliss GVS Pharma acquisition.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 65% YoY revenue growth in FY26 to Rs 23,836 million
+3 more records
Product overview1 text field

Anupam Rasayan India Ltd is a specialty chemicals manufacturer operating as a custom manufacturer of specialty chemicals with a platform-plus-products architecture. The core offering is custom manufacturing of specialty chemicals through proprietary continuous flow chemistry, serving agrochemicals (approximately 45% revenue post-acquisition), pharmaceuticals (~9-10% and growing), and performance materials sectors. Key products include ETFA (Ethyl Trifluoroacetate) manufactured via their continuous flow chemistry platform, with global addressable market of $500-600 million. The company has expanded through acquisitions including US-based Jayhawk Fine Chemicals (advanced custom synthesis for electronics, aerospace, energy, polymers) and India-based Bliss GVS Pharma (finished dosage formulations including suppositories, injectables, tablets with WHO-GMP/EU-GMP approvals). The company operates 6 manufacturing sites with 30,000+ MPTA installed capacity, producing 60+ complex molecules across 30+ commercial chemistries, serving 80+ customers globally.

Product and service5 records
1Custom Manufacturing of Specialty Chemicals
CategorySpecialty Chemicals Manufacturing
Description

Custom manufacturing of specialty chemicals delivered to agrochemical, pharmaceutical, performance materials, and life sciences customers, supported by R&D capabilities, supply chain management, and backward-integrated facilities.

2ETFA (Ethyl Trifluoroacetate)
CategoryFluorinated Specialty Chemicals
Description

Fluorinated building block compound manufactured using proprietary continuous flow chemistry, serving as a critical input for pharmaceuticals, life sciences, and performance materials sectors.

3Pharmaceutical Formulations (via Bliss GVS Pharma)
CategoryPharmaceutical Formulations
Description

Finished dosage formulations including suppositories, injectables, and tablets manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities, serving regulated markets in Africa, Asia, Latin America, Europe, and the US.

4Advanced Custom Synthesis (via Jayhawk Fine Chemicals)
CategorySpecialty Chemicals - Custom Synthesis
Description

Custom synthesis capabilities for electronics, aerospace, energy, and polymers sectors in the US market, with a manufacturing facility in Kansas providing access to regulated North American markets and innovator customers.

5Custom Synthesis and CDMO Services
CategoryCDMO Services
Description

Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications, delivered to global enterprise customers under long-term contracts.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-23
Description

Acquisition of 43.3-48.2% stake in Bliss GVS Pharma Ltd for approximately ₹1,369 crore, with mandatory open offer for additional 26% stake at ₹299 per share. The acquisition marks entry into pharmaceutical formulations business with access to US FDA, WHO-GMP, and EU-GMP approved manufacturing facilities. Combined entity creates integrated pharmaceutical manufacturing platform from key starting materials to finished dosage formulations with access to regulated markets including Europe and the United States.

2Jayhawk Fine Chemicals Corporation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Acquisition of US-based Jayhawk Fine Chemicals Corporation for approximately $150 million, marking Anupam Rasayan's first manufacturing presence in the United States. The acquisition enhances global footprint and capabilities in high-value chemical segments for electronics and specialty materials. Jayhawk generates significant revenue from electronics, aerospace, energy, and polymers sectors in the US.

bisresearch.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian specialty chemicals manufacturer with a similar custom synthesis and complex molecule portfolio serving agrochemical, pharmaceutical, and performance chemical customers globally. Direct competitor for CDMO contracts in fluorination and intermediates.

TypeDirect peer
Description

Indian fluorinated specialty chemicals producer, the most direct competitor on Anupam's ETFA and other fluorinated building block product lines. Overlaps with Anupam's flow chemistry ambitions and pharma/agrochem customer base.

TypeDirect peer
Description

Indian API and custom synthesis manufacturer serving global pharma customers with complex molecules and CDMO services. Comparable business model targeting regulated pharma end markets like Anupam's pharmaceutical segment.

TypeDirect peer
Description

Indian agrochemical CDMO with a custom synthesis model serving global innovators, directly comparable to Anupam's largest agrochemical custom manufacturing segment. Similar enterprise sales motion and contract structure.

5SRF Limited
TypeDirect peer
Description

Indian specialty chemicals company with fluorochemicals, specialty gases, and intermediates exposure. Direct competitor across performance materials and selected pharma intermediates, including fluorinated chemistries.

TypeDirect peer
Description

Indian specialty chemicals and CDMO player serving pharma, agro, and nutrition end markets. Comparable custom synthesis capability and customer overlap with Anupam's agrochem/pharma verticals.

7Atul Limited
TypeDirect peer
Description

Indian integrated specialty chemicals manufacturer with multi-vertical exposure across agro, pharma, and performance chemicals. Comparable diversification strategy and complex molecule manufacturing.

TypeBroad incumbent
Description

Global specialty chemicals major with a broad portfolio including fluorinated materials and performance chemicals. Larger established player overlapping with Anupam's performance materials and fluorination platform.

TypeBroad incumbent
Description

Global specialty chemicals company serving agro, pharma, and industrial customers with intermediates and additives. Broader portfolio player overlapping with several of Anupam's chemistry platforms.

10Shandong Finzone Chemical (Jiangsu Yangnong) / generic Chinese fluorochemical producers
TypeEmerging player
Description

Chinese fluorinated specialty chemical producers with cost-advantaged capacity targeting similar pharma and agro end markets. Represents the principal competitive threat to Anupam's pricing on fluorinated intermediates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anupam Rasayan

Specialty Chemicals Manufacturinganupamrasayan.com

Anupam Rasayan is a publicly listed Indian custom manufacturer of specialty chemicals, producing complex molecules via proprietary continuous flow chemistry for 80+ global pharma, agrochemical, and performance-materials customers across eight manufacturing facilities in India and the US.

What Anupam Rasayan does

Anupam Rasayan India Limited is a publicly listed (NSE: ANURAS) custom manufacturer of specialty chemicals headquartered in Surat, Gujarat, India, with 1,700+ employees including 90+ scientists and 40+ years of industry experience. The company operates eight manufacturing facilities — six in India and two in the United States (acquired via Jayhawk Fine Chemicals in February 2026) — with a combined installed capacity of approximately 30,000+ MPTA, producing 60+ complex molecules across 30+ commercial chemistries for 80+ global customers in agrochemicals (51% of pre-acquisition revenue), pharmaceuticals, and performance materials/electronics.

The company's core technology is a proprietary continuous flow chemistry platform, which in June 2026 enabled it to become the world's first commercial producer of Ethyl trifluoroacetate (ETFA) — a fluorinated building block serving pharma, life sciences, and performance materials end-markets with a $500-600 million global addressable market. Its products include custom-synthesized agrochemical intermediates and active ingredients, pharmaceutical intermediates and (via Bliss GVS Pharma, announced May 2026) finished dosage formulations including suppositories, injectables, and tablets manufactured at US FDA, WHO-GMP, and EU-GMP approved facilities, and advanced custom synthesis for electronics, aerospace, energy, and polymers via the Jayhawk acquisition.

Anupam Rasayan generates revenue through a B2B custom synthesis and contract development/manufacturing (CDMO) model with quote-based pricing under long-term contracts. FY26 revenue reached Rs 23,836 million (approximately $285M USD), up 65% YoY, with FY26 net profit of Rs 170.12 crore (+82.24% YoY). The company sells directly to enterprise customers in regulated markets via wholly-owned subsidiaries in the US (Delaware, Kansas), Europe (Basel), Japan (Tokyo), and the UAE (Dubai). Recent strategic positioning includes an EcoVadis Silver Medal (Top 15% globally, score 77), UN Global Compact signatory status, and a 2027 net-zero energy target with 39.5% renewable energy share already achieved.

Anupam Rasayan firmographics

Firmographics
Name
Anupam Rasayan
Legal name
Anupam Rasayan India Limited
Website
https://anupamrasayan.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Anupam Rasayan is a publicly listed Indian custom manufacturer of specialty chemicals, producing complex molecules via proprietary continuous flow chemistry for 80+ global pharma, agrochemical, and performance-materials customers across eight manufacturing facilities in India and the US.
Ownership category
akta.pro rank

Anupam Rasayan industry classification

Industry
Product category
Specialty Chemicals Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Industrial Organic Chemicals (2860), Chemicals & Allied Products (2800), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYAFABAIAI
Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Agrochemical Formulation & Toll Manufacturing
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Specialty chemicals manufacturing
  • Custom chemical synthesis
  • Pharmaceutical intermediates
  • Agrochemical intermediates
  • Continuous flow chemistry

Where Anupam Rasayan is headquartered

Location

Headquarters

HQ city
Sachin
HQ country
India
HQ region
Asia

Offices6 records

Markets served

Anupam Rasayan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Specialty Chemicals Manufacturing: Custom manufacturing of specialty chemicals for agrochemicals (51% of revenue pre-acquisition), pharmaceuticals, and performance materials segments. Revenue generated through long-term contracts and custom synthesis projects with 80+ global customers.
  2. Custom Synthesis Services: Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications. Contributed to significant revenue growth with 65% YoY increase in FY26.
  3. Pharmaceutical Formulations: Entry into finished dosage formulations through acquisition of Bliss GVS Pharma, expanding from key starting materials into finished dosage formulations with access to US FDA, WHO-GMP, and EU-GMP approved facilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom manufacturing services with quote-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Anupam Rasayan product offering

Product offering

Core offering

Anupam Rasayan is a custom manufacturer of specialty chemicals operating 8 manufacturing facilities across India and the United States with combined capacity of about 66,000 metric tonnes. The company produces 60+ complex molecules across 30+ commercial chemistries, serving agrochemicals, pharmaceuticals, performance materials, and life sciences sectors. It also operates a CDMO business for custom synthesis of complex molecules and has expanded into finished dosage pharmaceutical formulations through the Bliss GVS Pharma acquisition.

Product overview

Anupam Rasayan India Ltd is a specialty chemicals manufacturer operating as a custom manufacturer of specialty chemicals with a platform-plus-products architecture. The core offering is custom manufacturing of specialty chemicals through proprietary continuous flow chemistry, serving agrochemicals (approximately 45% revenue post-acquisition), pharmaceuticals (~9-10% and growing), and performance materials sectors. Key products include ETFA (Ethyl Trifluoroacetate) manufactured via their continuous flow chemistry platform, with global addressable market of $500-600 million. The company has expanded through acquisitions including US-based Jayhawk Fine Chemicals (advanced custom synthesis for electronics, aerospace, energy, polymers) and India-based Bliss GVS Pharma (finished dosage formulations including suppositories, injectables, tablets with WHO-GMP/EU-GMP approvals). The company operates 6 manufacturing sites with 30,000+ MPTA installed capacity, producing 60+ complex molecules across 30+ commercial chemistries, serving 80+ customers globally.

Differentiator

Problem solved

Functional benefit

Products and services

  • Custom Manufacturing of Specialty Chemicals Custom manufacturing of specialty chemicals delivered to agrochemical, pharmaceutical, performance materials, and life sciences customers, supported by R&D capabilities, supply chain management, and backward-integrated facilities.
  • ETFA (Ethyl Trifluoroacetate) Fluorinated building block compound manufactured using proprietary continuous flow chemistry, serving as a critical input for pharmaceuticals, life sciences, and performance materials sectors.
  • Pharmaceutical Formulations (via Bliss GVS Pharma) Finished dosage formulations including suppositories, injectables, and tablets manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities, serving regulated markets in Africa, Asia, Latin America, Europe, and the US.
  • Advanced Custom Synthesis (via Jayhawk Fine Chemicals) Custom synthesis capabilities for electronics, aerospace, energy, and polymers sectors in the US market, with a manufacturing facility in Kansas providing access to regulated North American markets and innovator customers.
  • Custom Synthesis and CDMO Services Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications, delivered to global enterprise customers under long-term contracts.

Quantifiable outcome

  • 65% YoY revenue growth in FY26 to Rs 23,836 million
  • +3 more outcomes

Companies that use Anupam Rasayan

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Anupam Rasayan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Anupam Rasayan partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bliss GVS Pharma LtdcoreStrategic or Co-development Partner · 23 May 2026Acquisition of 43.3-48.2% stake in Bliss GVS Pharma Ltd for approximately ₹1,369 crore, with mandatory open offer for additional 26% stake at ₹299 per share. The acquisition marks entry into pharmaceutical formulations business with access to US FDA, WHO-GMP, and EU-GMP approved manufacturing facilities. Combined entity creates integrated pharmaceutical manufacturing platform from key starting materials to finished dosage formulations with access to regulated markets including Europe and the United States.
  • Jayhawk Fine Chemicals CorporationcoreStrategic or Co-development Partner · 11 December 2025Acquisition of US-based Jayhawk Fine Chemicals Corporation for approximately $150 million, marking Anupam Rasayan's first manufacturing presence in the United States. The acquisition enhances global footprint and capabilities in high-value chemical segments for electronics and specialty materials. Jayhawk generates significant revenue from electronics, aerospace, energy, and polymers sectors in the US.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Anupam Rasayan competitors and assessment

Company assessment

Direct peers

  • Aarti Industries: Indian specialty chemicals manufacturer with a similar custom synthesis and complex molecule portfolio serving agrochemical, pharmaceutical, and performance chemical customers globally. Direct competitor for CDMO contracts in fluorination and intermediates.
  • Navin Fluorine International: Indian fluorinated specialty chemicals producer, the most direct competitor on Anupam's ETFA and other fluorinated building block product lines. Overlaps with Anupam's flow chemistry ambitions and pharma/agrochem customer base.
  • Divi's Laboratories: Indian API and custom synthesis manufacturer serving global pharma customers with complex molecules and CDMO services. Comparable business model targeting regulated pharma end markets like Anupam's pharmaceutical segment.
  • PI Industries: Indian agrochemical CDMO with a custom synthesis model serving global innovators, directly comparable to Anupam's largest agrochemical custom manufacturing segment. Similar enterprise sales motion and contract structure.
  • SRF Limited: Indian specialty chemicals company with fluorochemicals, specialty gases, and intermediates exposure. Direct competitor across performance materials and selected pharma intermediates, including fluorinated chemistries.
  • Jubilant Ingrevia: Indian specialty chemicals and CDMO player serving pharma, agro, and nutrition end markets. Comparable custom synthesis capability and customer overlap with Anupam's agrochem/pharma verticals.
  • Atul Limited: Indian integrated specialty chemicals manufacturer with multi-vertical exposure across agro, pharma, and performance chemicals. Comparable diversification strategy and complex molecule manufacturing.

Broad incumbents

  • Solvay: Global specialty chemicals major with a broad portfolio including fluorinated materials and performance chemicals. Larger established player overlapping with Anupam's performance materials and fluorination platform.
  • LANXESS: Global specialty chemicals company serving agro, pharma, and industrial customers with intermediates and additives. Broader portfolio player overlapping with several of Anupam's chemistry platforms.

Emerging players

  • Shandong Finzone Chemical (Jiangsu Yangnong) / generic Chinese fluorochemical producers: Chinese fluorinated specialty chemical producers with cost-advantaged capacity targeting similar pharma and agro end markets. Represents the principal competitive threat to Anupam's pricing on fluorinated intermediates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Anupam Rasayan social profiles

Digital presence

Anupam Rasayan compliance and trust

Trust signal

Compliance6 records

Anupam Rasayan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anupam Rasayan leadership team

Management profile

Number of profiles

Profiles10 records

Anupam Rasayan subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Anupam Rasayan funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anupam Rasayan M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anupam Rasayan

What does Anupam Rasayan do?

Anupam Rasayan is a custom manufacturer of specialty chemicals operating 8 manufacturing facilities across India and the United States with combined capacity of about 66,000 metric tonnes. The company produces 60+ complex molecules across 30+ commercial chemistries, serving agrochemicals, pharmaceuticals, performance materials, and life sciences sectors. It also operates a CDMO business for custom synthesis of complex molecules and has expanded into finished dosage pharmaceutical formulations through the Bliss GVS Pharma acquisition.

Is Anupam Rasayan a public or private company?

Anupam Rasayan is a public company. It is classified as public and is currently operating.

When was Anupam Rasayan founded?

Anupam Rasayan was founded in 1984. It employs 501 to 1,000 people.

Where is Anupam Rasayan based?

Anupam Rasayan is headquartered in Sachin, India, in the Asia region.

How does Anupam Rasayan make money?

Three revenue lines are on record. Specialty Chemicals Manufacturing is the primary driver. The others are custom Synthesis Services and pharmaceutical Formulations.

Who are Anupam Rasayan's main competitors?

Direct peers on record are Aarti Industries, Navin Fluorine International, Divi's Laboratories, PI Industries, SRF Limited, Jubilant Ingrevia and Atul Limited. Broad incumbents are Solvay and LANXESS. Shandong Finzone Chemical (Jiangsu Yangnong) / generic Chinese fluorochemical producers is listed as an emerging player.

Does Anupam Rasayan have an API?

No public API is recorded for Anupam Rasayan.

What industry is Anupam Rasayan in?

Anupam Rasayan's product category is Specialty Chemicals Manufacturing. Its primary akta.pro industry code is AFABAIAI, Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 32541 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaAnupam Rasayan posts strong half-year resultsAnupam Rasayan India reported first-half FY27 revenue of ₹1,489 crore, up 21% year-on-year, and EBITDA of ₹377 crore, up 38%. The company also signed a six-year supply deal with a US speciality metal manufacturer and acquired a controlling stake in Bliss GVS Pharma, signaling diversification into pharmaceuticals.Simply Wall StAnupam Rasayan India Ltd Just Recorded A 44% Revenue Beat: Here's What Analysts ThinkAnupam Rasayan India Ltd reported Q2 revenue of ₹8.1b, a 44% beat, with statutory earnings of ₹15.09 in line with forecasts. Analysts now forecast 2027 revenue of ₹41.5b, up 58% from last year, but downgraded EPS estimates. The consensus price target rose 11% to ₹1,263.CNBCTV18Anupam Rasayan sees stronger FY27 second half as acquisitions, new contract drive growth - CNBC TV18Anupam Rasayan reported 10% year-on-year growth in Q2FY27, with sequential growth above 20% and full consolidation expected from Bliss GVS Pharma next quarter. The company guided to ₹2,400-2,500 crore topline for the second half and a new supply contract starting in Q3FY27, expected to add ₹100-150 crore this fiscal year.TradingViewANURAS: H1 growth strengthened margins as Bliss expanded the platform and H2 revenue guidance reached INR 2,400–2,500 croreAnupam Rasayan India Ltd. reported H1 FY27 total income up 21% year-on-year and EBITDA up 38%, with margins improving. Bliss GVS expanded the pharma platform, and the company guided H2 consolidated revenue to INR 2,400–2,500 crore.TradingViewAnupam Rasayan India Q2 2027 Earnings Call Is LiveAnupam Rasayan India's Q2 2027 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.ScanXAnupam Rasayan posts record FY26 revenue of ₹2,384 croreAnupam Rasayan India Ltd reported record consolidated revenue of ₹2,384 crore for FY26, up 64.6% from ₹1,448 crore in FY25. The company declared a final dividend of ₹1.50 per share and acquired Jayhawk Fine Chemicals and a controlling stake in Bliss GVS Pharma. Management attributed growth to improved capacity utilisation and disciplined working capital.The Times of IndiaCPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookIndian pharma companies at CPHI Milan are shifting from generic exports to partnerships, licensing, and CDMO/CDMO services. Cipla, Mankind, and Cadila are pursuing these opportunities, while companies like Anupam Rasayan target higher-value products and 'Europe plus one' manufacturing. Geopolitical risks and tariffs are prompting diversification across geographies.The Times of IndiaAnupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugsAnupam Rasayan, after acquiring Bliss, plans to push pharma sales in the US and Europe, targeting 70-80% capacity utilization. Pharma now accounts for about 20% of revenue, with the Rs 1,750 crore Bliss deal adding formulation capability. US sales could start this year, with Europe next.CNBCTV18How Anupam Rasayan plans to double Bliss GVS Pharma's rev in three years - CNBC TV18Anupam Rasayan expects its acquisition of Bliss GVS Pharma to double the target unit's revenue to ₹2,000 crore over two to three years, nearly double its FY26 revenue of ₹927 crore. The acquisition would combine Anupam's starting materials business with Bliss GVS' finished dosage formulations, and the company projects 20-25% organic growth and a 24-26% EBITDA margin for FY27.The Times of IndiaAnupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan completed its acquisition of Bliss GVS Pharma, a branded formulations company, after the mandatory open offer. The deal, funded by a Rs 300 crore term loan and Rs 1,450 crore from investors, adds the company's 150+ brands and manufacturing facilities. The combined platform is expected to generate pro-forma revenue of over Rs 4,000 crore and EBITDA of about Rs 834 crore.